Ovarian Cancer Resource Center: Featured Article

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The FDA set a Prescription Drug User Fee act date in the second quarter of 2025 for durvalumab plus chemotherapy in muscle-invasive bladder cancer.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

Nemvaleukin with and without pembrolizumab yielded promising anti-tumor activity and was well tolerated in patients with advanced solid tumors.